Last reviewed · How we verify
Plasma-Lyte A In Plastic Container (Sodium Acetate)
Sodium acetate works by inhibiting the enzyme carbonic anhydrase 1, which plays a crucial role in maintaining acid-base balance in the body.
Normosol-R pH 7.4 is an electrolyte replacement solution indicated for acute extracellular fluid volume losses in surgery, trauma, burns, or shock. The solution provides isotonic electrolyte composition approximating normal plasma with physiologic sodium-to-chloride ratio and bicarbonate alternates. No contraindications are known, though additives may be incompatible and aseptic technique is required. The product is particularly valuable for blood transfusion priming and is compatible with both young and old packed red blood cells.
At a glance
| Generic name | Sodium Acetate |
|---|---|
| Sponsor | Pfizer |
| Drug class | sodium acetate |
| Target | Carbonic anhydrase 1, Carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1983 |
Mechanism of action
ISOPLATE SOLUTION contains the following key components to maintain platelet function:Sodium chloride for osmolarityAcetate to fuel platelet metabolismGluconate or phosphate for bufferingMagnesium and potassium to reduce platelet activation1,2 This solution has no pharmacological effect; the solution provides the appropriate components for platelet function while allowing for lower volume of plasma in the platelet product during storage.. Sodium chloride for osmolarity. Acetate to fuel platelet metabolism. Gluconate or phosphate for buffering. Magnesium and potassium to reduce platelet activation1,2.
Approved indications
Common side effects
- HOT FLUSH
- Lymphocyte count decreased
- NAUSEA
- NIGHT SWEATS
- Neutrophil count decreased
- Nausea
- HEADACHE
- Hiccups
- Glomerular filtration rate decreased
- Diarrhoea
- Decreased appetite
- NASOPHARYNGITIS
Serious adverse events
- Anaphylaxis
- Cardiac arrest
- Circulatory collapse
- Myocardial rupture
- Pulmonary edema
- Peptic ulcer with perforation and hemorrhage
- Pancreatitis
- Convulsions
- Increased intracranial pressure with papilledema
- Paraparesis/paraplegia
Drug interactions
- Additives (general)
- Calcium salts
- Citrated blood
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma-Lyte A In Plastic Container CI brief — competitive landscape report
- Plasma-Lyte A In Plastic Container updates RSS · CI watch RSS
- Pfizer portfolio CI